JP2023110019A5 - - Google Patents

Download PDF

Info

Publication number
JP2023110019A5
JP2023110019A5 JP2023090905A JP2023090905A JP2023110019A5 JP 2023110019 A5 JP2023110019 A5 JP 2023110019A5 JP 2023090905 A JP2023090905 A JP 2023090905A JP 2023090905 A JP2023090905 A JP 2023090905A JP 2023110019 A5 JP2023110019 A5 JP 2023110019A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
glutathione
bicarbonate
molar ratio
ascorbic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023090905A
Other languages
English (en)
Japanese (ja)
Other versions
JP7617179B2 (ja
JP2023110019A (ja
Filing date
Publication date
Priority claimed from JP2020545050A external-priority patent/JP7339955B2/ja
Application filed filed Critical
Publication of JP2023110019A publication Critical patent/JP2023110019A/ja
Publication of JP2023110019A5 publication Critical patent/JP2023110019A5/ja
Application granted granted Critical
Publication of JP7617179B2 publication Critical patent/JP7617179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023090905A 2017-11-17 2023-06-01 安定したアスコルビン酸組成物およびそれを使用する方法 Active JP7617179B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762588300P 2017-11-17 2017-11-17
US62/588,300 2017-11-17
US201862684700P 2018-06-13 2018-06-13
US62/684,700 2018-06-13
JP2020545050A JP7339955B2 (ja) 2017-11-17 2018-11-16 安定したアスコルビン酸組成物およびそれを使用する方法
PCT/US2018/061686 WO2019099946A1 (en) 2017-11-17 2018-11-16 Stable ascorbic acid compositions and methods of using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020545050A Division JP7339955B2 (ja) 2017-11-17 2018-11-16 安定したアスコルビン酸組成物およびそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2023110019A JP2023110019A (ja) 2023-08-08
JP2023110019A5 true JP2023110019A5 (https=) 2023-09-15
JP7617179B2 JP7617179B2 (ja) 2025-01-17

Family

ID=66539933

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020545050A Active JP7339955B2 (ja) 2017-11-17 2018-11-16 安定したアスコルビン酸組成物およびそれを使用する方法
JP2023090905A Active JP7617179B2 (ja) 2017-11-17 2023-06-01 安定したアスコルビン酸組成物およびそれを使用する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020545050A Active JP7339955B2 (ja) 2017-11-17 2018-11-16 安定したアスコルビン酸組成物およびそれを使用する方法

Country Status (22)

Country Link
US (4) US11497786B2 (https=)
EP (2) EP3710036B1 (https=)
JP (2) JP7339955B2 (https=)
KR (1) KR102731292B1 (https=)
CN (1) CN111615395B (https=)
AU (2) AU2018367674B2 (https=)
BR (1) BR112020009910A2 (https=)
CA (1) CA3082900A1 (https=)
DK (1) DK3710036T3 (https=)
ES (1) ES3008699T3 (https=)
FI (1) FI3710036T3 (https=)
HR (1) HRP20241746T1 (https=)
HU (1) HUE069510T2 (https=)
IL (1) IL274635B2 (https=)
LT (1) LT3710036T (https=)
MX (2) MX2020005087A (https=)
PH (1) PH12020550645A1 (https=)
PL (1) PL3710036T3 (https=)
PT (1) PT3710036T (https=)
SG (1) SG11202004540QA (https=)
SI (1) SI3710036T1 (https=)
WO (1) WO2019099946A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017362500B2 (en) 2016-11-17 2024-09-26 Renovion, Inc. Treatment of Respiratory Tract Diseases and Infections with Ascorbic Acid Compositions
BR112020009910A2 (pt) 2017-11-17 2020-11-03 Renovion, Inc. composições de ácido ascórbico estáveis e métodos de usar as mesmas
CN111413492A (zh) * 2020-04-30 2020-07-14 山东大学 一种用于检测新型冠状病毒covid-2019肺炎的方法及系统
EP3970718A1 (en) * 2020-09-18 2022-03-23 Charité - Universitätsmedizin Berlin New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators
WO2023014887A1 (en) * 2021-08-04 2023-02-09 The Trustees Of Indiana University Methods of treating compromised lung function and assessing clinical improvement
CN113995744B (zh) * 2021-10-13 2023-03-17 温州肯恩大学 一种组合物及其抗菌应用
KR20240131358A (ko) * 2022-01-04 2024-08-30 레노비온, 아이엔씨. 글루타치온 염을 포함하는 수용액
WO2023141237A1 (en) * 2022-01-20 2023-07-27 Cell and Molecular Tissue Engineering, LLC Methods and products to detect, minimize and treat trap-related tissue reactions and tissue injury associated with medical devices
WO2024016019A1 (en) * 2022-07-15 2024-01-18 Renovion, Inc. Compositions and methods for treatment of subjects suffering from a sars-cov-2 infection
WO2025231041A1 (en) * 2024-04-30 2025-11-06 Renovion, Inc. Methods for reducing symptoms in subjects suffering from bronchiectasis and other pulmonary diseases

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2606903A (en) 1944-03-29 1952-08-12 Physiological Chemicals Compan Ascorbic acid addition compound of sulfathiazole
US5070085A (en) 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US4968716A (en) 1987-04-10 1990-11-06 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US4861783A (en) 1988-04-26 1989-08-29 E. I. Du Pont De Nemours And Company 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
US5304724A (en) 1988-09-09 1994-04-19 Entravision, Inc. Tissue irrigating solution
US5238683A (en) 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
DK0494405T3 (da) 1991-01-10 1996-11-18 Transcend Therapeutics Inc Anvendelse af thiazolidin-4-carboxylatderivater til behandling af lungesygdomme
US6764693B1 (en) 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5626883A (en) 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
WO1998019694A1 (en) 1996-11-01 1998-05-14 Xoma Corporation Therapeutic uses of bpi protein products in cystic fibrosis patients
DE69739663D1 (de) 1996-12-31 2009-12-31 Antioxidant Pharmaceuticals Co Pharmazeutische glutathionpräparate und methoden zu dern verabreichung
US6896899B2 (en) 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US5906811A (en) 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US6470894B2 (en) 1997-09-19 2002-10-29 Thione International, Inc. Glutathione, green tea, grape seed extract to neutralize tobacco free radicals
US5829449A (en) 1997-09-19 1998-11-03 Thione International, Inc. Smoking products containing antioxidants
US6415798B1 (en) 1997-09-19 2002-07-09 Thione International, Inc. Antioxidants to neutralize tobacco free radicals
US6228347B1 (en) 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
CA2339473A1 (en) 1998-08-04 2000-02-17 John V. Kosbab Nutrient and therapeutic compositions for the treatment of cancer
US6312734B1 (en) 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
KR100390630B1 (ko) * 1999-07-02 2003-07-07 이희발 항 산화제를 함유한 복막투석액
DE19935763B4 (de) 1999-07-27 2006-03-02 Jenning, Volkhard, Dr. Zusammensetzung eines Redoxsystems zur Stabilisierung von Retinoiden in Präparaten zur äußerlichen Anwendung
US7045152B2 (en) 1999-09-08 2006-05-16 Duke University Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US20020037855A1 (en) 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
EP1282416A2 (en) 2000-05-19 2003-02-12 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
US6485950B1 (en) 2000-07-14 2002-11-26 Council Of Scientific And Industrial Research Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions
CA2425489C (en) 2000-10-16 2011-05-17 Duke University Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
US20020165207A1 (en) 2001-05-02 2002-11-07 Richard Rosenbloom Compositions and methods for the treatment of diabetic neuropathy
WO2002053161A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
CA2446064A1 (en) 2001-05-02 2002-11-07 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
EP1474158B1 (en) 2001-12-18 2009-10-14 Brassica Foundation for Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase ii detoxification enzymes
AUPS019802A0 (en) 2002-01-31 2002-02-21 Chemstop Pty Ltd Nutrient formulation
US20040229815A1 (en) 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
AU2004296178B2 (en) 2003-12-04 2011-03-24 The United States Of America As Represented By The Department Of Veterans Affairs Gallium inhibits biofilm formation
US20050271726A1 (en) 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
DE102004035113A1 (de) 2004-07-20 2006-02-16 Degussa Ag alpha-Liponsäure enthaltende Zusammensetzung bei cystischer Fibrose
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
JP5112876B2 (ja) 2004-11-07 2013-01-09 エフ. ギルフォード ティモシー 還元型グルタチオン経口投与のためのリポソーム処方物
CA2587883A1 (en) 2004-11-17 2006-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusale M Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma
US8703198B2 (en) 2005-03-02 2014-04-22 Aquatrove Biosciences Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof
JP2008538752A (ja) 2005-04-12 2008-11-06 クレオ コスメティック アンド ファーマスーティカルカンパニー エルエルシー 角膜組織を生体外保存するための組成物および方法
US20060258599A1 (en) 2005-04-27 2006-11-16 Melanie Childers Methods and composition for the treatment of cystic fibrosis and related illnesses
WO2006125262A1 (en) 2005-05-24 2006-11-30 Environmental Biotechnology Crc Pty Limited Methods and compositions for regulating biofilm development
WO2007024876A2 (en) 2005-08-24 2007-03-01 The Board Of Trustees Of Leland Stanford Junior University Methods for treating and monitoring inflammation and redox imbalance in cystic fibrosis
EP2016187B1 (en) 2006-05-10 2016-07-06 Laclede, Inc. Compositions for use in the enzymatic treatment of lung disorders
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
WO2009023355A2 (en) 2007-05-25 2009-02-19 Ironwood Pharmaceuticals, Inc. Compositions and methods for reducing the toxicity of certain toxins
WO2009001884A1 (ja) 2007-06-26 2008-12-31 Kyowa Hakko Bio Co., Ltd. 酸化型グルタチオン錠
JP2011026204A (ja) 2007-11-26 2011-02-10 Rei Furukawa タバコの煙を吸入することにより引き起こされる疾患の予防及び/又は治療用組成物
WO2009099132A1 (ja) * 2008-02-05 2009-08-13 Kyowa Hakko Bio Co., Ltd. グルタチオンの保存安定性向上方法
US9289462B2 (en) 2008-09-17 2016-03-22 Terry Gage Method for medical treatment utilizing glutathione
FR2941374B1 (fr) 2009-01-28 2011-03-11 Alaxia Utilisation d'une association synergique d'ions hypothiocyanites et/ou hypohalites et de lactoferrine pour la preparation pour le traitement de la mucoviscidose
US20120093947A1 (en) 2009-02-27 2012-04-19 United States Department Of Veterans Affairs Method of treating reactive airway disease
GB0908174D0 (en) 2009-05-13 2009-06-24 Isis Innovation Steroid containing composition and uses thereof
CN101987195B (zh) 2009-08-06 2012-07-18 重庆市力扬医药开发有限公司 经口腔粘膜吸收的还原型谷胱甘肽药物
IT1401504B1 (it) 2010-08-02 2013-07-26 Cattarini Mastelli Composizione comprendente glutatione reduttasi e glutatione ossidato
WO2012027603A2 (en) 2010-08-26 2012-03-01 Clarity Products, Limited Liability Company Therapeutic consumable compositions for reduction of facial flush effect incident to alcohol consumption in persons with deficient activity of the aldehyde dehydrogenase gene-aldh2
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
CN102100904B (zh) 2011-01-25 2013-04-24 成都卓阳生物科技有限公司 还原型谷胱甘肽经皮吸收制剂及其制备方法
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US20130084336A1 (en) 2011-06-27 2013-04-04 Albert Einstein College Of Medicine Of Yeshiva University Enhanced nitric oxide delivery and uses thereof
CN102329370B (zh) 2011-09-22 2015-07-22 山东金城医药化工股份有限公司 还原型谷胱甘肽单钠盐的制备方法
WO2014070769A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
WO2014126594A1 (en) 2013-02-15 2014-08-21 Guilford Frederick Timothy Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione
US20140234397A1 (en) 2013-02-15 2014-08-21 Lou Ann Brown Treatment of klebsiella pneumoniae with liposomally formulated glutathione
ITPD20130052A1 (it) 2013-03-01 2014-09-02 Enologica Vason S P A Procedimento di vinificazione e prodotto per uso enologico atto ad essere utilizzato in detto procedimento di vinificazione
WO2016037166A1 (en) 2014-09-07 2016-03-10 Yu Zhang Novel anti-oxidant compositions and methods of delivery
WO2016067283A1 (en) 2014-10-30 2016-05-06 Rice Howard Virucidal compositions comprising tannins for nasal and pulmonary administration
WO2016088116A1 (en) 2014-12-05 2016-06-09 University Health Network Use of antioxidants as radio-protective agents
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
AU2017298202A1 (en) 2016-07-16 2019-02-07 Lauranell Harrison Burch Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
AU2017362500B2 (en) * 2016-11-17 2024-09-26 Renovion, Inc. Treatment of Respiratory Tract Diseases and Infections with Ascorbic Acid Compositions
BR112020009910A2 (pt) * 2017-11-17 2020-11-03 Renovion, Inc. composições de ácido ascórbico estáveis e métodos de usar as mesmas
JP7356438B2 (ja) 2017-11-21 2023-10-04 メドンケアー ファーマスーティカル カンパニー リミテッド ジシクロプラチンを含有する組み合わせ製剤、その調製及びその使用
WO2019113543A1 (en) 2017-12-07 2019-06-13 Reven, Llc Compositions and methods for the treatment of metabolic conditions
CN113365513B (zh) 2018-10-23 2025-04-25 G·E·霍格 用于治疗肺的组合物和方法

Similar Documents

Publication Publication Date Title
JP2023110019A5 (https=)
RU2001119990A (ru) Применение антагониста AT-1 или модулятора рецептора АТ-2 для лечения болезней, связанных с увеличением содержания рецепторов АТ-1 или АТ-2
HRP20241746T1 (hr) Stabilni pripravci askorbinske kiseline i postupci za njihovu uporabu
GB2454044A (en) Sustained release composition to the nasal mucosa comprising nitric oxide, and a device therefore
US9861647B2 (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
WO2015014209A1 (zh) 稳定渗透压的丙酮酸药物组成及其在健康人和肺病病人中的排毒作用
IT202000005026A1 (it) Lattoferrina per uso inalatorio ad azione antivirale
CN106667974A (zh) 一种吸入用硫酸特布他林溶液制备方法
JPH10500966A (ja) 経口吸入もしくは吹き込みにより投与する為の化合物、及び組成物
WO2016036273A1 (ru) Лекарственное средство для профилактики и лечения заболеваний дыхательных путей
WO2018018851A1 (zh) 奥司他韦羧酸盐酸盐及其雾化剂的制备方法
WO2021198940A1 (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物
CA2701388C (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
KR20240116930A (ko) 이부프로펜 및 아르기닌을 포함하는 약제학적 조성물
IL163736A (en) Tiotropium containing powdered preparations, method of their preparation and uses thereof for the manufacture of a medicament suitable for inhalation
WO2022046668A1 (en) Compositions and methods for reducing the transmissivity of illnesses
JPH09227373A (ja) 抗インフルエンザウイルス剤
CN105326789B (zh) 氨溴索沙丁胺醇溶液剂
CN105456240B (zh) 氨溴索沙丁胺醇气雾剂
CN102686232B (zh) 用于治疗干咳的来自罗望子树种子的多糖聚合物
RU2190422C1 (ru) Аэрозоль для ингаляций фармацевтической композиции глутовент и способ лечения с его использованием
US20170020838A1 (en) Treatment for respiratory disease
Hardy et al. Positive pressure respiration in the treatment of irritant pulmonary edema due to chlorine gas poisoning
JP2024517432A (ja) 気道の炎症/線維化病変および肝臓病変の治療における官能化キトサンの使用
RU2326670C1 (ru) Способ комплексной интенсивной терапии острого стенозирующего ларинготрахеита у детей